Pharmacokinetics of Envarsus in pediatric kidney transplant recipients – phase 1 pilot conversion study
Jon Jin Kim,
Laura Lawless,
David Marshall
et al.
Abstract:IntroductionTacrolimus is the standard immunosuppressant for pediatric kidney transplants and is routinely administered twice daily (BD‐tac). Envarsus (LCP‐tac), an extended‐release formulation, is approved for adults but not for pediatric patients.MethodsWe conducted a pilot open‐label phase 1 study in stable pediatric kidney transplant recipients (age < 18 at the time of study). Our primary objective was to compare the pharmacokinetics (Pk) of LCP‐tac versus BD‐tac. We conducted two 24‐h Pk studies: pre‐c… Show more
Set email alert for when this publication receives citations?
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.